SPTX Financials

Income Statement
MetricQ3 2026Q2 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
30.3M
-53.9%
65.8M
R&D
23.9M
-3.0%
24.6M
SG&A
6.5M
-84.3%
41.2M
Operating Income
-30345000
+53.9%
-65808000
EBITDA
-30318000
+53.9%
-65782000
Net Income
-26394000
+57.8%
-62600000
EPS (Basic)
$-0.49
+72.5%
$-1.78
EPS (Diluted)
$-0.49
+72.5%
$-1.78
Shares (Diluted)
53.5M
+51.9%
35.2M
Seaport Therapeutics (SPTX) — Financials